Regeneron Pharmaceuticals and Sanofi's experimental injectable drug dupilumab reduced asthma attacks by 87% during a Phase II -More- Stop banking and start building with GE Capital, Healthca…
NextBio recently announced a multi-year collaboration with Sanofi (NYSE:SNY) aimed at using NextBio Clinical to incorporate patient omics and clinical data into Sanofi's drug research and...Read the w…
Much excitement over Sanofi/Regeneron asthma drug…
Sanofi and Regeneron Pharmaceuticals have announced positive Phase 2a study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe allergic asthma.
